Jaeb Center for Health Research conducted a randomized controlled trial evaluating the impact of automated insulin delivery ...

The stock's fall snapped a two-day winning streak.

Of the hundreds of millions of people living with diabetes, most liv. Dexcom wants to make sure they have tools to manage it.

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Technosphere insulin, a rapid-acting human insulin administrated through an inhaler, was associated with reductions in HbA1c ...

The latest trend in health and fitness tracking may sound familiar: wearing continuous glucose monitors (CGMs). Many people ...

Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient ...

AI-enhanced glucose monitoring provides predictive analytics and personalized insights for better blood sugar management.

Medical device companies presented new data this week at the Advanced Technologies & Treatments for Diabetes conference.

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of $98.00. The ...

Over 13 weeks, adults with type 2 diabetes using an automated insulin delivery (AID) system had a 0.6-percentage point ...

Shares of DexCom Inc. rallied 3.79% to $73.38 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 1.08% to 5,675.29 and the Dow ...